Cargando…

Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy

Cryptococcus neoformans infections occur mostly in immunodeficient individuals, being the most common opportunistic fungal central nervous system (CNS) infection in HIV seropositive patients. Moreover, other conditions affecting host immunity, such as hematologic malignancies, organ transplantation...

Descripción completa

Detalles Bibliográficos
Autores principales: Cunha Pereira, Tatiana, Rb-Silva, Rita, Félix Soares, Rita, Domingues, Nelson, Mariz, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7512028/
https://www.ncbi.nlm.nih.gov/pubmed/33024550
http://dx.doi.org/10.12688/f1000research.24816.2
_version_ 1783586073621823488
author Cunha Pereira, Tatiana
Rb-Silva, Rita
Félix Soares, Rita
Domingues, Nelson
Mariz, José
author_facet Cunha Pereira, Tatiana
Rb-Silva, Rita
Félix Soares, Rita
Domingues, Nelson
Mariz, José
author_sort Cunha Pereira, Tatiana
collection PubMed
description Cryptococcus neoformans infections occur mostly in immunodeficient individuals, being the most common opportunistic fungal central nervous system (CNS) infection in HIV seropositive patients. Moreover, other conditions affecting host immunity, such as hematologic malignancies, organ transplantation and immunosuppressive drugs are implicated as risk factors. The authors present a case of a 48-year-old male with Hodgkin Lymphoma for 26 years and submitted to several lines of treatment, diagnosed with cryptococcal meningitis while on therapy with brentuximab. The patient presented with positive cerebral spinal fluid (CSF) cryptococcal antigen plus positive blood cultures. He was put under induction antifungal treatment with liposomal amphotericin B and flucytosine, as well as corticosteroid therapy with dexamethasone with headache improvement and a favorable clinical evolution. There are no reported cases of cryptococcal meningoencephalitis under CD30-directed monoclonal antibody. Furthermore, this case illustrates the risk of Cryptococcus neoformans infection in immunocompromising conditions other than HIV, underlining the need of considering this differential diagnosis when physicians face an opportunistic neuroinfection.
format Online
Article
Text
id pubmed-7512028
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-75120282020-10-05 Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy Cunha Pereira, Tatiana Rb-Silva, Rita Félix Soares, Rita Domingues, Nelson Mariz, José F1000Res Case Report Cryptococcus neoformans infections occur mostly in immunodeficient individuals, being the most common opportunistic fungal central nervous system (CNS) infection in HIV seropositive patients. Moreover, other conditions affecting host immunity, such as hematologic malignancies, organ transplantation and immunosuppressive drugs are implicated as risk factors. The authors present a case of a 48-year-old male with Hodgkin Lymphoma for 26 years and submitted to several lines of treatment, diagnosed with cryptococcal meningitis while on therapy with brentuximab. The patient presented with positive cerebral spinal fluid (CSF) cryptococcal antigen plus positive blood cultures. He was put under induction antifungal treatment with liposomal amphotericin B and flucytosine, as well as corticosteroid therapy with dexamethasone with headache improvement and a favorable clinical evolution. There are no reported cases of cryptococcal meningoencephalitis under CD30-directed monoclonal antibody. Furthermore, this case illustrates the risk of Cryptococcus neoformans infection in immunocompromising conditions other than HIV, underlining the need of considering this differential diagnosis when physicians face an opportunistic neuroinfection. F1000 Research Limited 2020-08-12 /pmc/articles/PMC7512028/ /pubmed/33024550 http://dx.doi.org/10.12688/f1000research.24816.2 Text en Copyright: © 2020 Cunha Pereira T et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Cunha Pereira, Tatiana
Rb-Silva, Rita
Félix Soares, Rita
Domingues, Nelson
Mariz, José
Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy
title Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy
title_full Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy
title_fullStr Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy
title_full_unstemmed Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy
title_short Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy
title_sort case report: cryptococcal meningitis in hodgkin’s lymphoma patient receiving brentuximab-vedotin therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7512028/
https://www.ncbi.nlm.nih.gov/pubmed/33024550
http://dx.doi.org/10.12688/f1000research.24816.2
work_keys_str_mv AT cunhapereiratatiana casereportcryptococcalmeningitisinhodgkinslymphomapatientreceivingbrentuximabvedotintherapy
AT rbsilvarita casereportcryptococcalmeningitisinhodgkinslymphomapatientreceivingbrentuximabvedotintherapy
AT felixsoaresrita casereportcryptococcalmeningitisinhodgkinslymphomapatientreceivingbrentuximabvedotintherapy
AT dominguesnelson casereportcryptococcalmeningitisinhodgkinslymphomapatientreceivingbrentuximabvedotintherapy
AT marizjose casereportcryptococcalmeningitisinhodgkinslymphomapatientreceivingbrentuximabvedotintherapy